South West Yorkshire Area Prescribing Committee Red Drug Classification Listing - Printed on 18/06/2008 Red Classification
• Prescribing responsibility should remain with the consultant or specialist clinician. • Medicines with one or more of the following criteria should be categorised as RED.
o are not licensed for any indication in the UK; o require long-term on-going specialist monitoring of efficacy; o require long-term on-going specialist monitoring of toxicity (either because of
difficulty in recognising side effects or high cost/availability of investigations to identify toxicity);
o are specifically designated as hospital only by product licence or the MHRA; o are being used as part of a hospital based clinical trial; o are new drugs or a new indication for an existing drug prior to formal request
Always check the latest Summary of Product Characteristics for the licensed indications Drug Indications Drug Indications
Nausea/vomiting with highly emetogenic chemotherapy
Produced by the South West Yorkshire Area Prescribing Committee Red Drug Classification List for use in the population covered by the geographical areas of Page 1 of 3 Calderdale, Kirklees and Wakefield Printed on 18/06/2008 Drug Indications Drug Indications
prevention and treatment of nausea and vomiting
Metastatic colorectal cancer used with 5-FU and folinic acid
Moderately severe to severe Alzheimers disease.
Recombinant human macrophage-colony stimulating factor -
Inflammatory bowel disease (Unlicensed Use)
AIDS patients. CMV disease in immunocompromised & AIDS
patients. use in Liver Transplant patients.
Treatment of hepatitis B and C, patients not tolerating conventional
Produced by the South West Yorkshire Area Prescribing Committee Red Drug Classification List for use in the population covered by the geographical areas of Page 2 of 3 Calderdale, Kirklees and Wakefield Printed on 18/06/2008 Drug Indications Drug Indications
Prevention of skeletal related events (pathological fractures, spinal
compression, radiation/surgery to bone, or tumour-induced
Adjunctive treatment of seizures in Lennox-Gastaut syndrome
and neuropathic pain in multiple sclerosis (unlicensed controlled drug available on named patient basis only)
Bisphosphonate – osteolytic lesions, hypercalcaemia and bone pain associated with skeletal masses in breast cancer or multiple myeloma
Combination treatment of metastatic breast cancer
Antineoplastic; induction of remission in acute promyelocytic leukaemia
Non-opioid analgesic administered by intrathecal infusion
Produced by the South West Yorkshire Area Prescribing Committee Red Drug Classification List for use in the population covered by the geographical areas of Page 3 of 3 Calderdale, Kirklees and Wakefield Printed on 18/06/2008
Journal of Health Science, 50 (5) 456–465 (2004) Studies on the Properties and Real Existence of Aqueous Solution Systems that are Assumed to Have Antioxidant Activities by the Action of “Active Hydrogen” Atsushi Hiraoka,*, a Masumi Takemoto, a Takahiro Suzuki, a Atsuko Shinohara, b Momoko Chiba, b Mika Shirao, c and Yoshihiro Yoshimura d aDepartment of Patholo
CLINICIAN’S CORNER Palliative Care for Patients With Amyotrophic Lateral Sclerosis “Prepare for the Worst and Hope for the Best” Amyotrophic lateral sclerosis (ALS) is a devastating ter- minal neurodegenerative disease with a highly predict- THE PATIENT’S STORY able clinical course such that palliative care should be- gin at or soon after diagnosis. The outcome is certain i
South West Yorkshire